Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

Autoantibodies to the Thyrotropin Receptor

Smith, B. R., McLachlan, S. M., & Furmaniak, J. (1988) · Endocrine Reviews · doi:10.1210/edrv-9-1-106 · Cited by 578 · see citing works

HLA‐DQB1 and ‐DQA1 typing by PCR amplification with sequence‐specific primers (PCR‐SSP) in 2 hours

Olerup, O., Aldener, A., & Fogdell, A. (1993) · Tissue Antigens · doi:10.1111/j.1399-0039.1993.tb01991.x · Cited by 555 · see citing works

Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential.

Fowell, D. J., & MASON, D. W. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.177.3.627 · Cited by 437 · see citing works

Induction of tolerance by monoclonal antibody therapy

Benjamin, R. J., & Waldmann, H. (1986) · Nature · doi:10.1038/320449a0 · Cited by 299 · see citing works

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial

van Oosten, B. W., Lai, M., Hodgkinson, S. J., Barkhof, F., Miller, D., MOSELEY, I. F., Thompson, A. J., Rudge, P., McDougall, A., McLeod, J., et al. (1997) · Neurology · doi:10.1212/wnl.49.2.351 · Cited by 262 · see citing works

A CTLA‐4 gene polymorphism is associated with both Graves' disease and autoimmune hypothyroidism

Kotsa, K., Watson, P. F., & Weetman, A. P. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.1710996.x · Cited by 258 · see citing works

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis

Moreau, T., Coles, A. J., Wing, M. G., Isaacs, J. D., Hale, G., Waldmann, H., & Compston, A. (1996) · Brain · doi:10.1093/brain/119.1.225 · Cited by 249 · see citing works

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

Moreau, T., Scolding, N. J., Compston, A., Thorpe, J. W., Miller, D., MOSELEY, I. F., Hale, G., Waldmann, H., Clayton, D. G., Wing, M. G., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91339-0 · Cited by 186 · see citing works

Thyroiditis in T cell-depleted rats. Influence of strain, radiation dose, adjuvants and antilymphocyte serum.

Penhale, W. J., FARMER, A. E., & Irvine, W. J. (1975) · PubMed · Cited by 118 · see citing works

Autoimmunity in multiple sclerosis

Keyser, J. D. (1988) · Neurology · doi:10.1212/wnl.38.3.371 · Cited by 95 · see citing works

Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferonin vitro

Hirsch, R. L., PANITCH, H. S., & Johnson, K. P. (1985) · Journal of Clinical Immunology · doi:10.1007/bf00915335 · Cited by 95 · see citing works

Delayed occurrence of Graves' disease after immune restoration with HAART

Gilquin, J., Viard, J.-P., Jubault, V., Sert, C., & Kazatchkine, M. D. (1998) · The Lancet · doi:10.1016/s0140-6736(05)60398-4 · Cited by 86 · see citing works

Autoimmune Hyperthyroidism in Patients With Multiple Sclerosis Treated With Interferon Beta-1b

Schwid, S. R., Goodman, A. D., & Mattson, D. H. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550210095020 · Cited by 81 · see citing works

Immunologic responses of progressive multiple sclerosis patients treated with an anti‐T‐cell monoclonal antibody, anti‐T12

Hafler, D. A., Fallis, R. J., Dawson, D. M., et al. (1986) · Neurology · doi:10.1212/wnl.36.6.777 · Cited by 75 · see citing works

A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants

Cobbold, S. P., Rebello, P., Davies, H. F. S., et al. (1990) · Journal of Immunological Methods · doi:10.1016/0022-1759(90)90335-s · Cited by 44 · see citing works

Measurement of thyroid stimulating immunoglobulins in a new cell line transfected with a functional human TSH receptor (JPO9 cells), compared with an assay using FRTL‐5 cells

Michelangell, V. P., Munro, D., Poon, C., et al. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03017.x · Cited by 42 · see citing works

Opposite Changes in Serum Soluble CD8 in Patients at the Active Stages of Graves' and Hashimoto's Diseases

Watanabe, M., Amino, N., Hochito, K., et al. (1997) · Thyroid · doi:10.1089/thy.1997.7.743 · Cited by 23 · see citing works

Disease activity and the immune set in multiple sclerosis: blood markers for immunotherapy

Coles, A. J., Wing, M. G., & Compston, D. A. (1998) · Multiple Sclerosis Journal · doi:10.1177/135245859800400327 · Cited by 9 · see citing works

Untitled work

Kordower (1999) · doi:10.1002/1531-8249(199909)46:3

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198 · see citing works

The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease

Afzali, B., Lombardi, G., Lechler, R. I., & Lord, G. M. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03356.x · Cited by 762 · see citing works

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

Brennan, F. R., Morton, L. D., Spindeldreher, S., Kiessling, A., Allenspach, R., Hey, A., Müller, P., Frings, W., & Sims, J. (2010) · mAbs · doi:10.4161/mabs.2.3.11782 · Cited by 250 · see citing works

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

Tuohy, O., Costelloe, L., Hill-Cawthorne, G., Bjornson, I., Harding, K., Robertson, N., May, K., Button, T., Azzopardi, L., Kousin-Ezewu, O., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307721 · Cited by 238 · see citing works

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

Cossburn, M., Pace, A. A., Jones, J., Ali, R., Ingram, G., Baker, K., Hirst, C., Zajicek, J., Scolding, N., Boggild, M., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318228bec5 · Cited by 216 · see citing works

Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)

Walsh, M., Chaudhry, A., & Jayne, D. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.081661 · Cited by 178 · see citing works

Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis

Daniels, G. H., Vladic, A., Brinar, V., Zavalishin, I., Valente, W., Oyuela, P., Palmer, J., & Margolin, D. H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2201 · Cited by 150 · see citing works

Inflammation in multiple sclerosis: the good, the bad, and the complex

Martino, G., Adorini, L., Rieckmann, P., Hillert, J., Kallmann, B., Comi, G., & Filippi, M. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00223-5 · Cited by 142 · see citing works

Drugs affecting thyroid function

Barbesino, G. (2010) · Thyroid · doi:10.1089/thy.2010.1635 · Cited by 146 · see citing works

Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease

Chen, F., Day, S. L., Metcalfe, R. A., Sethi, G., Kapembwa, M. S., Brook, M. G., Churchill, D., de Ruiter, A., Robinson, S., Lacey, C. J., et al. (2005) · Medicine · doi:10.1097/01.md.0000159082.45703.90 · Cited by 142 · see citing works

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

Lundin, J., Porwit-MacDonald, A., Rossmann, E. D., Karlsson, C., Edman, P., Rezvany, M. R., Kimby, E., Österborg, A., & Mellstedt, H. (2004) · Leukemia · doi:10.1038/sj.leu.2403258 · Cited by 118 · see citing works

Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117 · see citing works

Immune reconstitution syndrome and the thyroid

Weetman, A. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.07.003 · Cited by 87 · see citing works

Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features

Pariani, N., Willis, M., Muller, I., Healy, S., Nasser, T., McGowan, A., Lyons, G., Jones, J., Chatterjee, K., Dayan, C., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00359 · Cited by 84 · see citing works

2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy

Muller, I., Moran, C., Lecumberri, B., Decallonne, B., Robertson, N., Jones, J., & Dayan, C. M. (2019) · European Thyroid Journal · doi:10.1159/000500881 · Cited by 78 · see citing works

Graves’ disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction

French, M. A., Lewin, S. R., Dykstra, C., Krueger, R., Price, P., & Leedman, P. J. (2004) · AIDS Research and Human Retroviruses · doi:10.1089/088922204773004879 · Cited by 59 · see citing works

Graves’ disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently?

Weetman, A. P. (2014) · Clinical Endocrinology · doi:10.1111/cen.12427 · Cited by 46 · see citing works

Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy; evidence that TRAb may precede thyroid dysfunction by many years

Muller, I., Willis, M., Healy, S., Nasser, T., Loveless, S., Butterworth, S., Zhang, L., Draman, M. S., Taylor, P. N., Robertson, N., et al. (2018) · Thyroid · doi:10.1089/thy.2018.0232 · Cited by 34 · see citing works

A Case Report of Graves’ Disease Induced by the Anti-Human Programmed Cell Death-1 Monoclonal Antibody Pembrolizumab in a Bladder Cancer Patient

Yajima, K., & Akise, Y. (2019) · Case Reports in Endocrinology · doi:10.1155/2019/2314032 · Cited by 13 · see citing works

Drug effects and thyroid function

Feldt-Rasmussen, U., & Rasmussen, Å. K. (2018) · Encyclopedia of Endocrine Diseases · doi:10.1016/b978-0-12-801238-3.96002-1 · Cited by 4 · see citing works

Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis

Iovino, A., Aruta, F., Carotenuto, A., et al. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.12.024 · Cited by 3 · see citing works

Autoimmunity

Crowley, H., & Huber, B. T. (2010) · doi:10.1002/9780470688618.taw0118

Autoimmunity and Heavy Metals

Bigazzi, P. E. (1994) · Lupus · doi:10.1177/096120339400300604 · Cited by 86 · see citing works

Low-dose exposure to inorganic mercury accelerates disease and mortality in acquired murine lupus.

Via, C. S., Nguyen, P., Niculescu, F. I., et al. (2003) · Environmental Health Perspectives · doi:10.1289/ehp.6064 · Cited by 79 · see citing works

From autoimmunity to autoimmune disease

Salinas, G. (2012) · UvA-DARE (University of Amsterdam)